MYC and lymphoma: Therefore, cells with secondary mutations eliminating the function of the TP53 tumor suppressor or inducing a gain of function of BCL2 (or related factors) are selected because they counteract c-MYC induced apoptosis and facilitate proliferation and progression to a full blown lymphoma (91).